Alkem Laboratories Ltd.

Financial

	Alkem Laboratories	Cipla	Mankind Pharma
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	173.0 .	273.0 .	55.0 .
Number of ANDA's Approved By USFDA	146.0 .	193.0 .	32.0 .
Number of ANDA's Filed in Europe	18.0	n/a	n/a
Number of ANDA's Approved in Europe	12.0	n/a	n/a
Number of ANDA's Filed in Australia	42.0	n/a	n/a
Number of ANDA's Approved by Australia	32.0	n/a	n/a
Domestic Sales Growth - YoY	7.9 %	8.9 %	n/a
R&D as a % of Total Sales	3.3 %	6.1 %	2.15 %
Financials
5 yr Average ROE	16.74 %	11.43 %	23.48 %
5yr average Equity Multiplier	1.42	1.39	1.4
5yr Average Asset Turnover Ratio	0.9	0.76	1.02
5yr Avg Net Profit Margin	13.14 %	10.96 %	16.52 %
Price to Book	5.95	4.63	11.0
P/E	37.24	31.02	53.68
5yr Avg Cash Conversion Cycle	0.57 Days	-3.69 Days	-45.92 Days
Inventory Days	55.43 Days	59.85 Days	60.23 Days
Days Receivable	40.86 Days	44.13 Days	19.33 Days
Days Payable	116.85 Days	114.64 Days	132.42 Days
5yr Average Interest Coverage Ratio	24.09	23.71	47.23
5yr Avg ROCE	22.27 %	15.24 %	31.06 %
5yr Avg Operating Profit Margin	19.27 %	22.51 %	25.32 %
5 yr average Debt to Equity	0.22	0.13	0.07
5yr CAGR Net Profit	5.29 %	12.9 %	17.25 %
5yr Average Return on Assets	11.73 %	8.36 %	16.73 %
Shareholdings
Promoter Holding	56.74 %	33.47 %	74.88 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-3.42 %	-3.26 %	-1.62 %
Change in Mutual Fund Holding (3 Yrs)	5.03 %	2.19 %	6.74 %

Business

	Alkem Laboratories	Cipla	Mankind Pharma
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 100.0 New ventures 0 Pharmaceuticals 0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0	Product Wise Break-Up Anti-infectives 0 Gastro - Intestinal 0 Cardiovascular 0 Pharmaceutical 95.78 Anti-Diabetic 0 Urology 0 Pharmaceutical 0 Gynaecology 0 Dermatology 0 Respiratory 0 VMN 0 Pain/Analgesics 0 New ventures 4.22 Neuro/CNS 0	Product Wise Break-Up Anti-infectives 17.0 Gastrointestinal 10.0 Cardiovascular 14.0 Pharmaceuticals 0 Anti-Diabetic 8.0 Urology 5.0 Pharmaceutical 0 Gynaecology 7.0 Dermatology 6.0 Respiratory 9.0 VMN 10.0 Pain/Analgesics 5.0 New ventures 0 Neuro/CNS 3.0 Others 6.0
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Anti-Infective 37.6 Gastro Intestinal 18.6 Pain Management 10.9 Vitamins / Minerals / Nutrients 10.3 Anti - Diabetes 4.0 Gynecology 4.0 Central Nervous System (CNS) 3.8 Respiratory 3.3 Derma 2.8 Cardiac Science 2.3 Urology 0 Antivirals 0 Neuro /CNS 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Opthal/Otologicals 0 Oncology 0 Anti Diabetic 0 Others 2.4	Therapeutic Area Wise Break-Up - Domestic Central Nervous System (CNS) 2.3 Derma 2.7 Oncology 0 Gastro Intestinal 5.8 Vitamins 0 Anti-Infective 0 Central Nervous System (CNS) 0 Pain Management 0 Gynaec. 0 Vitamins / Minerals / Nutrients 0 Anti - Diabetes 0 Urology 4.8 Antivirals 3.1 Ophthalmology 3.1 Cardiac Science 0 Gynecology 0 Respiratory Systems 38.9 Anti - Diabetes 3.8 Antineoplast 0 Others 35.5	-
Location Wise Break-Up	Location Wise Break-Up India 67.17 USA 30.81 SAGA 0 Europe 0 Global API 0 Rest of the World 0 Emerging Markets 0 North America 0 Nepal 0 Sri Lanka 0 Bangladesh 0 Others 2.02	Location Wise Break-Up Nepal 0 SAGA 12.0 Global API 2.0 USA 0 Emerging Markets 0 India 44.0 Europe 0 Sri Lanka 0 North America 29.0 Rest of the World 11.0 Bangladesh 0 Others 2.0	Location Wise Break-Up Nepal 0 SAGA 0 Global API 0 USA 0 Emerging Markets 0 India 92.0 Europe 0 Sri Lanka 0 North America 0 Rest of the World 0 Bangladesh 0 Others 8.0
Asset Break-Up	Asset Break-Up India 85.09 USA 13.19 South Africa 0 Others 1.72	Asset Break-Up South Africa 16.85 USA 30.05 India 47.79 Others 5.31	-

Alkem Laboratories Ltd.

SIGN UP FOR FREE